However, most established protocols use subcutaneous injection
Sometimes, its not about working harder, its about supporting your body differently
In a separate study, a post-hoc analysis focused on safety data for a female subgroup from a previous Phase 3 study that included 36 women using GLP-1 drugs during the 28-day study
[5] [6] This approach typically results in a safe, sustainable weight loss of approximately 0.5 to 1 kg per week
Tirzepatide is a GLP-1/GIP receptor agonist that helps regulate appetite, digestion, and blood sugar levels
Track weekly weight, daily appetite on a 1 to 10 scale, food intake, and exercise